Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

39 results about "Subjective tinnitus" patented technology

Subjective tinnitus. Subjective tinnitus is the most frequent type of tinnitus. It can have many possible causes, but most commonly it results from hearing loss. When the tinnitus is caused by disorders of the inner ear or auditory nerve it is called otic (from the Greek word for ear).

Totally implantable hearing prosthesis

The invention comprises a totally implantable hearing prosthesis for hearing impaired persons. An inertial vibrational element is hermetically sealed and implanted in bone between the lateral and superior semicircular canals without breaching the integrity of the canals. The vibrational element is adapted to vibrate the walls of the canals and the fluids contained therein, thereby vibrating contiguous fluids within the cochlea thus stimulating hair cells and creating a hearing percept. The invention can also be adapted to be a tinnitus masking system, and / or used in combination with a coehlear implant hearing system.
Owner:MED EL ELEKTROMEDIZINISCHE GERAETE GMBH

Method and device for tinnitus therapy

ActiveUS20060167335A1Ear treatmentElectric tinnitus maskersEqual-loudness contourHearing perception
A method and device for tinnitus therapy. The method includes generating pure sounds, each having a predetermined frequency, within an audible range, and waiting for a user to press an input button when the user hears the pure sound. Then, the hearing characteristics of the user are interpreted in conjunction with equal loudness contours. From this interpretation, either a tinnitus masking method or a tinnitus retraining therapy are selected according to the hearing characteristics of the user.
Owner:SAMSUNG ELECTRONICS CO LTD

Systems for and methods of transcranial direct current electrical stimulation

A system according to the present invention provides a portable, non-invasive device adapted to deliver electrical stimulation to a brain, such as to treat tinnitus. Such system is preferably a head-worn system configured to provide transcranial direct current electrical stimulation (tDCS) to a patient, where a therapy based at least partially thereon may be self-administered by the patient. tDCS is a non-invasive method of brain stimulation to treat tinnitus, or other neurological indications, that may provide significant relief. Methods according to the present invention include preferably brief sessions of anodal tDCS to assist in determining adequate electrode location and stimulus intensity by producing transient decreases in tinnitus intensity. Methods may also or alternatively include a number of sessions of cathodal tDCS at a confirmed electrode location and stimulus intensity to provide sustained tinnitus relief. Methods may also or alternatively include a number of maintenance sessions to prolong the sustained relief.
Owner:NDI MEDICAL

Methods for the treatment of tinnitus induced by cochlear excitotoxicity

InactiveUS20060063802A1Suppress and reduce NMDA receptor mediated aberrant activityPreventing and treating tinnitusCompounds screening/testingBiocideNR1 NMDA receptorTotal Deafness
The invention relates to methods for the prevention and / or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and / or formulations for local administration to the inner ear. The tinnitus to be prevented and / or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +1

Aural rehabilitation system and a method of using the same

A system 2 and method 64 for neurological rehabilitation or training is disclosed. The system 2 can be used to improve listening, comprehension, and communication. The system 2 can be controlled automatically by a remote device 6 or manually by a physician's device 4. The system 2 can store data in, and retrieve data from a database 10 for analysis, reporting and execution. The system 2 can adapt and adjust based on the subject's performance. The system 2 can be used to treat hearing loss, tinnitus or other audiological health problems.
Owner:NEUROTONE

Methods for the treatment of tinnitus induced by cochlear excitotoxicity

ActiveUS20050214338A1Suppress and reduce NMDA receptor mediated aberrant activityPreventing and treating tinnitusBiocideHalogenated hydrocarbon active ingredientsNR1 NMDA receptorTotal Deafness
The invention relates to methods for the prevention and / or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and / or formulations for local administration to the inner ear. The tinnitus to be prevented and / or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, sudden deafness, or other cochlear excitotoxic-inducing occurrence.
Owner:AURIS MEDICAL AG

RNA interference mediated inhibition of retinolblastoma (RBI) gene expression using short interfering nucleic acid (siNA)

This invention relates to compounds, compositions, and methods useful for modulating retinoblastoma (RB1) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of retinoblastoma gene expression and / or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of retinoblastoma genes. Such small nucleic acid molecules are useful, for example, for treating, preventing, inhibiting, or reducing hearing loss, deafness, tinnitus, motion and balance disorders, cancer and proliferative diseases and any other disease, condition, trait or indication that can respond to the level of retinoblastoma in a cell or tissue, alone or in combination with other treatments or therapies.
Owner:SIRNA THERAPEUTICS INC

Prevention and treatment of hearing disorders

Compositions, and methods of use thereof, are provided for the prevention, treatment or alleviation of symptoms of hearing are provided. Embodiments of the methods employ zonisamide as the sole active pharmaceutical agent or a combination of zonisamide and another pharmaceutical agent, such as an antioxidant, a NMDA antagonist, an SSRI or a combined SSRI / NMDA antagonist agent. Other embodiments of the method involve the use of zonisamide alone or in combination with another API to prevent, treat or ameliorate one or more symptoms of hearing loss. Hearing disorders treatable with the invention include noise-induced hearing loss, drug-induced hearing loss, central auditory hearing disorder (CAPD), tinnitus and presbyacusis.
Owner:CYPRESS BIOSCI

Implantable medical devices with multiple transducers

The present invention relates to implantable medical devices for improving sound perception by individuals with severe to profound hearing loss or tinnitus. In particular, the present invention provides methods and devices for stimulating structures of the ear via multiple signal transducers.
Owner:MED EL ELEKTROMEDIZINISCHE GERAETE GMBH

Endosteal electrode

An implantable tissue-stimulating device comprising an elongate electrode carrier member (11) having a plurality of electrodes thereon. The electrodes are preferably disposed in a linear array on the carrier member (11) and are adapted to apply a preselected tissue stimulation to the cochlea. The carrier member (11) is preformed from a resiliently flexible biocompatible silicone and extends from a distal end (12) to a stop member (13). The carrier member (11) is adapted for intracochlear but extraluminar insertion within the cochlea of an implantee. In particular, the carrier member (11) is adapted to be implanted in the crevice (21) between the spiral ligament (22) and the endosteum (23) of the lateral wall of the cochlea (20). This is a quite different location to the normal placement of the cochlear implant electrode array in the scala tympani (24) of the cochlea (20). The placement of the carrier member (11) is designed to avoid any breach of the internal ducts of the cochlea (20), such as the scala tympani (24) and scala vestibuli (25) so that the normal hydrodynamic behaviour of the cochlea (20) is not affected by any intrusive device. By preservng the normal hydrodynamic behaviour of the cochlea (20), use of the carrier member (11) maximises the possibility of also preserving any hearing of the implantee that is offered by the cochlea (20). Use of the device in a system for masking or treating the symptoms of tinnitus is also described.
Owner:COCHLEAR LIMITED

Tinnitus treatment device

A tinnitus treatment device includes a sound generation device and a receiver unit connected to the sound generation device. The receiver unit is positioned in an open-ear configuration within the ear canal of a user and is dimensioned so as to reduce insertion loss and / or occlusion effects. The sound generation device is located in a housing positioned behind the user's ear.
Owner:BAUMAN NATAN

High fidelity hearing restoration

InactiveUS20050013445A1Accurately measuring hearing lossElectrotherapyAudiometeringRestoration methodElectrophonic hearing
Method for accurately measuring hearing loss includes the steps of selecting a series of audio tones within the normal range of hearing (502) and then measuring a relative sensitivity of a test subject with respect to the ability to hear each of the audio tones, exclusive of the effects of tinnitus. (504, 506, 508, 510, 512) The relative sensitivity of the test subject to hear the tones can be measured by determining (510) for each tone an intensity necessary for the test subject to hear the tones at a subjectively equal loudness level which is selected to exceed a perceived level of noise attributable to tinnitus for the test subject.
Owner:TECH LICENSING CORP (US)

2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones

InactiveUS20050245517A1BiocideOrganic active ingredientsNervous systemNeonatal cerebral hemorrhage
The present invention provides novel 2-pyridinyl[7(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones with at least one substituent on both the 2- and 4-pyridinyl ring having the chemical structure of formula I: The invention further provides compositions and methods employing the novel 2-pyridinyl[7-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones of formula I to modulate GABA and GABAA receptor physiology to elicit therapeutic responses in mammalian subjects to alleviate neurological or psychiatric disorders, including stroke, head trauma, epilepsy, pain, migraine, mood disorders, anxiety, post traumatic stress disorder, obsessive compulsive disorders, mania, bipolar disorders, schizophrenia, seizures, convulsions, tinnitus, neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis and Parkinson's disease, Huntington's chorea, depression, bipolar disorders, mania, trigeminal and other neuralgia, neuropathic pain, hypertension, cerebral ischemia, cardiac arrhythmia, myotonia, substance abuse, myoclonus, essential tremor, dyskinesia and other movement disorders, neonatal cerebral hemorrhage, and spasticity, as well as other psychiatric and neurological disorders mediated by GABA and / or GABAA receptors.
Owner:SKOLNICK PHIL +1

Soft, middle-ear electrode for suppressing tinnitis

A soft, ball-shaped middle-ear electrode is inserted and wedged into the natural cavity that exists in front of the round window. An electrical pulse generator connected to the soft, ball-shaped electrode provides electrical stimulation to the region surrounding the round window for the purpose of suppressing tinnitus or to improve hearing.
Owner:BOSTON SCI NEUROMODULATION CORP

Endosteal electrode

An implantable tissue-stimulating device comprising an elongate electrode carrier member (11) having a plurality of electrodes thereon. The electrodes are preferably disposed in a linear array on the carrier member (11) and are adapted to apply a preselected tissue stimulation to the cochlea. The carrier member (11) is preformed from a resiliently flexible biocompatible silicone and extends from a distal end (12) to a stop member (13). The carrier member (11) is adapted for intracochlear but extraluminar insertion within the cochlea of an implantee. In particular, the carrier member (11) is adapted to be implanted in the crevice (21) between the spiral ligament (22) and the endosteum (23) of the lateral wall of the cochlea (20). This is a quite different location to the normal placement of the cochlear implant electrode array in the scala tympani (24) of the cochlea (20). The placement of the carrier member (11) is designed to avoid any breach of the internal ducts of the cochlea (20), such as the scala tympani (24) and scala vestibuli (25) so that the normal hydrodynamic behaviour of the cochlea (20) is not affected by any intrusive device. By preservng the normal hydrodynamic behaviour of the cochlea (20), use of the carrier member (11) maximises the possibility of also preserving any hearing of the implantee that is offered by the cochlea (20). Use of the device in a system for masking or treating the symptoms of tinnitus is also described.
Owner:COCHLEAR LIMITED

Traditional Chinese medicine decoction piece combination preparation enhancing body immunity, preparation method therefor and combination package

The invention relates to a traditional Chinese medicine decoction piece preparation, and concretely relates to a traditional Chinese medicine decoction piece combination preparation enhancing body immunity, a preparation method therefor and combination package. The raw materials of the traditional Chinese medicine decoction piece combination preparation are composed of radix ophiopogonis, Chinese magnoliavine, prepared rehmannia root, cornus officinalis, tree peony bark, Chinese yam, poria cocos and oriental waterplantain rhizome. The traditional Chinese medicine decoction piece combination preparation has effects of nourishing kidney and lung, is used for treating lung and kidney yin deficiency, tidal fever, night sweating, pharynx dryness, dizziness, tinnitus and soreness of loins and knees, can enhance body immunity and has functions of anti-fatigue and conditioning of the sub-health state.
Owner:SHANGHAI JINCHENG PHARMACEUTICAL CO LTD

Health-care red wine and preparation method thereof

The invention discloses a health-care red wine and a preparation method thereof. The red wine base of the health-care red wine also comprises the following raw materials: 0.5-1.5 g / L raspberry, 0.01-1.5 g / L Rhodiola rosea, 0.01-1.5 g / L dodder, 0.01-1.5 g / L radix rehmanniae, 0.1-1 g / L Chinese wolfberry, 0.1-1 g / L mulberry, 0.05-0.8 g / L radix astragali, 0.05-0.8 g / L tuckahoe and 0.01-0.8 g / L licorice. The health-care red wine is prepared from multiple medicinal materials, has the functions of consolidating the constitution, benefiting the intestine, tonifying the kidney, strengthening the spleen, regulating sleep, warming the stomach, resisting aging and softening the blood vessels, has obvious effects on regulating frequent urination, precipitant urination, insomnia and discomfort caused by heart and cerebral vessels, and can relieve dizziness, tinnitus, nausea and other symptoms caused by cervical spondylosis.
Owner:徐昕然

Preparation method of health liquor

The invention discloses a preparation method of a health liquor. The preparation method comprises the following steps: step 1, making base liquor of the health liquor; step 2, making the health liquor by matching the base liquor and medicinal materials; step 3, sealing and storing; and step 4, bottling and packaging. In the processes of liquor brewing, medicinal material soaking and blending, medicinal properties can be completely released into the base liquor after the medicinal materials are soaked into the base liquor and therefore the utilization rate of the medicinal materials is high; the health liquor has outstanding treatment effects on poor sleep, gastrointestinal discomfort, aching lumbus and limp legs, kidney-deficiency impotence, physical and mental fatigue, tinnitus and heart palpitation, has the functions of worming and smoothening blood vessels, strengthening heart and tonifying yang and thus has good health care effect.
Owner:邓杨 +1

Preventive and/or Therapeutic Agents for Meniere's Disease

InactiveUS20070249695A1Effective preventionEffective therapeutic agentBiocideSenses disorderInner Ear DiseasesMedicine
The present invention relates to preventive and / or therapeutic agents for Meniere's disease, which comprise a leukotriene antagonist (such as pranlukast hydrate) as an active ingredient. Leukotriene antagonists (such as pranlukast hydrate) are effective in ameliorating various symptoms, such as hearing impairment, tinnitus, a feeling of fullness in the ear and vertigo, thus being useful as a preventive and / or therapeutic agent for Meniere's disease.
Owner:ONO PHARMA CO LTD +1

Substituted 5-aminomethyl-1H-pyrrole-2-carboxylic acid amides

Substituted 5-aminomethyl-1H-pyrrole-2-carboxylic acid amides, a process for the production thereof, pharmaceutical preparations containing these compounds and the use of these compounds in pharmaceutical preparations for treatment or inhibition of withdrawal symptoms, memory disorders, neurodegenerative diseases, epilepsy, cardiovascular disorders, water retention, intestinal motility disorders, urinary incontinence, anorexia, tinnitus, pruritus, depression, sexual dysfunction, airways diseases, food intake disorders, or type II (non-insulin-dependent) diabetes, or for anxiolysis, diuresis, suppression of the urinary reflex, reducing the addictive potential of opioids, modulating locomotor activity, influencing the cardiovascular system, or regulating electrolyte balance.
Owner:GRUNENTHAL GMBH

Noise damage tinnitus treating device

The present invention relates to a therapeutic equipment for curing tinnitus due to noise hazard. The connection relationship between all the composition circuits is noise source circuit, it is connected with one end of resistor R2 in amplification circuit by means of capacitor C1, the output end of amplification circuit is connected with one end of resistor R5 is active narrow-band filter, and the output end of the active narrow-band filter is connected with one end of resistor R9 of high pass active filter, and the output end of high pass active filter is connected with input end of power amplification circuit, and the output end of power amplification circuit is connected with earphone.
Owner:深圳市丰河环境工程技术有限公司上海分公司

Novel method and composition for local treatment of meniere's disease, tinnitus and/or hearing loss

Novel methods and compositions for the local treatment of Meniere's disease, tinnitus and hearing loss employ a therapeutically effective amount of a prostaglandin of the F-type to the inner ear. The treatment can be either continuous or intermittent and may involve the use of pumps, gels, or slow release drug inserts.
Owner:SYNFOLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products